Answer
In a screening study in healthy volunteers given a single 1,200 mg dose, oritavancin diphosphate was a nonspecific, weak inhibitor of CYP2C9 and CYP2C19 and a weak inducer of CYP3A4 and CYP2D6.
Sources for this answer
- Tenkasi 400 mg powder for concentrate for solution for infusionA. Menarini Farmaceutica Internazionale SRL · emc · SmPC §4.5 Interaction with other medicinal products · Version 4Document updated
Sources checked